Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 24, 2016
Scheduled abstracts will highlight 'real-world' and clinical trial experiences with technologies developed to treat patients with a range of cardiovascular diseases
Mar 22, 2016Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from...
- Mar 16, 2016
Two organizations to share intellectual property and stimulate the rapid development of medical devices to address unmet clinical needs
Mar 10, 2016FDA approval granted on the heels of CE Mark for the IntellaTip MiFi™ open-irrigated catheterFDA approval granted on the heels of CE Mark for the IntellaTip MiFi™ open-irrigated catheter
-
Mar 1, 2016
Boston Scientific will participate in the healthcare conference on March 15, 2016. Learn how to watch the webcast or replay.
-
Feb 25, 2016Chairman Pete Nicholas to retire; President and CEO Mike Mahoney to become chairman
Chairman Pete Nicholas to retire; President and CEO Mike Mahoney to become chairman
-
Feb 23, 2016
Boston Scientific will participate in the healthcare conference on March 8, 2016. Learn how to watch the webcast or replay.
Feb 23, 2016FDA-Approved ACUITY™ X4 Quadripolar Left Ventricular Leads to be used in Trial Pursuing MRI Labeling for Cardiac Defibrillation and Resynchronization SystemsACUITY™ X4 Quadripolar Left Ventricular Leads to be used in trial pursuing MRI labeling for cardiac defibrillation and resynchronization systems
Feb 22, 2016First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and AsiaFirst polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe
-
Feb 8, 2016CMS will cover percutaneous LAAC therapy for Medicare beneficiaries consistent with the FDA label when specific conditions are met
CMS will cover percutaneous LAAC therapy for Medicare beneficiaries consistent with the FDA label when specific conditions are met
